The Pharma Data

FEBRUARY 25, 2021

Food and Drug Administration (FDA) accepted for Priority Review the company’s Biologics License Application (BLA) for TicoVac , its tick-borne encephalitis (TBE) vaccine for active immunization to prevent TBE in individuals 1 year of age and older. About TicoVac (TBE vaccine, whole virus inactivated). This release contains forward?

FDA 52

FDA Vaccine Virus Clinical Trials 52

The Pharma Data

AUGUST 22, 2021

AZD7442 is a combination of two LAABs – tixagevimab (AZD8895) and cilgavimab (AZD1061) – derived from B-cells donated by convalescent patients after SARS-CoV-2 virus. Under the terms of the licensing agreement with Vanderbilt, AstraZeneca will pay single-digit royalties on future net sales. 2021 [link]. 2021.02.037.

Trials 52

Trials Vaccine Virus Pharmacokinetics 52

The Pharma Data

SEPTEMBER 30, 2021

That’s how easy it’s for SARS-CoV-2, the virus that causes COVID-19, to enter your nose. As prior work with other respiratory pathogens like influenza has shown, sterilizing immunity to virus re-infection requires adaptive immune responses within the tract and therefore the lung. Breathe in, exhale. doi: 10.1016/j.isci.2021.103037.

Vaccine 52

Vaccine Disease Immune Response Virus 52

The Pharma Data

JUNE 25, 2021

AstraZeneca today announced results from the STORM CHASER trial assessing the safety and efficacy of AZD7442, a long-acting antibody (LAAB) combination, for the prevention of symptomatic COVID-19 in participants recently exposed to the SARS-CoV-2 virus.

Trials 52

Trials Virus Long-Term Care Facilities Government 52

The Pharma Data

JANUARY 18, 2021

18, 2021 (GLOBE NEWSWIRE) — Sorrento Therapeutics, Inc. The fireside chat is scheduled to take place on Wednesday, January 20, 2021 at 2:30 PM ET. The fireside chat is scheduled to take place on Wednesday, January 20, 2021 at 2:30 PM ET. © 2021 Sorrento Therapeutics, Inc. SAN DIEGO, Jan.

Clinical Trials 40

Clinical Trials Small Molecule Trials Therapies 40

The Pharma Data

JANUARY 4, 2021

05, 2021 (GLOBE NEWSWIRE) — ViGeneron GmbH , a gene therapy company, today announced a global collaboration and licensing agreement with Biogen Inc. USA) to develop and commercialize gene therapy products based on adeno-associated virus (AAV) vectors to treat inherited eye diseases. MUNICH, Germany, Jan.

Therapies 52

Therapies Virus Disease Licensing 52

Agency IQ

MARCH 7, 2024

BY AMANDA CONTI | MAR 6, 2024 8:46 PM CST AgencyIQ’s quick primer on the influenza virus and how annual vaccine strains are selected Influenza viruses have caused untold illness and death through human history. A key part of the influenza virus’ ability to infect humans is hemagglutinin (HA), a glycoprotein found on the surface of the virus.

Vaccine 40

Vaccine FDA Virus Licensing 40

The Pharma Data

MARCH 11, 2021

Expected to enroll 415 participants; interim results expected in Q3 2021. The Companies expect interim results from this trial in the third quarter of 2021. MRT5500 is being developed under a collaboration and license agreement between Sanofi Pasteur and Translate Bio. About the Phase 1/2 clinical trial. About Translate Bio.

Clinical Trials 52

Clinical Trials Vaccine Trials Immune Response 52

The Pharma Data

OCTOBER 28, 2020

In the overall patient group with detectable virus at baseline, the average daily reduction in viral load through day 7 was a 0.36 About REGN-COV2 REGN-COV2 is a combination of two monoclonal antibodies (REGN10933 and REGN10987) and was designed specifically to block infectivity of SARS-CoV-2, the virus that causes COVID-19.

Virus 40

Virus Trials Clinical Trials Production 40

The Pharma Data

MAY 4, 2021

INDIANAPOLIS , May 4, 2021 /PRNewswire/ — Eli Lilly and Company (NYSE: LLY) announces new initiatives to help COVID-19 patients in India as part of its commitment to bring the full force of its scientific and medical expertise to attack the coronavirus pandemic around the world. Monitor patients for TB during Olumiant treatment.

Licensing 40

Licensing Licensing Therapies Laboratories 40

The Pharma Data

FEBRUARY 14, 2022

For most of 2021, limited global vaccine supply led to huge disparities in COVID-19 vaccine access, leaving billions of people – especially in low- and middle-income countries – unprotected against serious disease and death from COVID-19. We are opening the door to better health and wellbeing for our people.”. “At

Vaccine 52

Vaccine Licensing Licensing Science 52

The Pharma Data

APRIL 27, 2021

All doses expected to be delivered in 2021. NEW YORK and MAINZ, GERMANY, April 19, 2021 (GLOBE NEWSWIRE) — Pfizer Inc. NYSE: PFE) and BioNTech SE (Nasdaq: BNTX) today announced they will supply an additional 100 million doses of COMIRNATY®, the companies’ COVID-19 vaccine, to the 27 European Union (EU) member states in 2021.

Vaccine 52

Vaccine Clinical Trials Licensing Licensing 52

The Pharma Data

JUNE 26, 2021

JUNE 22 , 2021. The trial will evaluate the safety and immunogenicity of a monovalent flu vaccine candidate coding for the hemagglutinin protein of the A/H3N2 strain of the influenza virus. We look forward to evaluating the potential of these mRNA influenza vaccine candidates in this Phase 1 clinical trial.”.

Clinical Trials 52

Clinical Trials Vaccine Trials Immune Response 52

The Pharma Data

JANUARY 3, 2021

04, 2021 (GLOBE NEWSWIRE) — Passage Bio , Inc. Food and Drug Administration (FDA) has cleared an investigational new drug (IND) application for the company’s lead product candidate, PBGM01, an adeno-associated virus (AAV)-delivery gene therapy that is being studied for the treatment of infantile GM1 gangliosidosis (GM1).

Therapies 52

Therapies FDA Treatment Clinical Trials 52

The Pharma Data

MARCH 26, 2021

Data from the registrational COMET-ICE trial also will form the basis for a Biologics License Application (BLA) submission to the FDA. COMET-TAIL: A Phase 3 trial expected to begin in the second quarter of 2021 in high-risk adults to assess whether IM-administered VIR-7831 can reduce hospitalisation or death due to COVID-19.

Treatment 52

Treatment FDA Vaccine Trials 52

The Pharma Data

OCTOBER 25, 2020

The UK government’s COVID-19 Vaccine Taskforce and a contract research company called Open Orphan announced a $13 million (£10 million) plan to test investigational COVID-19 vaccines in volunteers who are then intentionally exposed to SARS-CoV-2, the virus that causes COVID-19. They will require regulatory and ethical approval.

Clinical Trials 52

Clinical Trials Vaccine Trials Virus 52

The Pharma Data

MAY 13, 2021

Posted 13 May 2021 | By Michael Mezher . Biogen licenses a stroke drug from Japanese drugmaker TMS ( BioPharmaDive ). Information for Blood Establishments Regarding FDA’s Determination that Zika Virus is no Longer a Relevant Transfusion-Transmitted Infection ( FDA ). In Focus: US. Medtech.

FDA Approval 52

FDA Approval FDA Vaccine Pharmacy 52

The Pharma Data

APRIL 18, 2022

Novavax licensed and transferred its manufacturing technologies to enable Takeda to develop and manufacture the vaccine at its facility in Hikari. We will disclose the Fiscal Year 2022 forecast at the Fiscal Year 2021 financial results announcement scheduled in May 2022. TAK-019 Clinical Trial. ml dose of TAK-019 at both vaccinations.

Vaccine 52

Vaccine Clinical Trials Trials Virus 52

The Pharma Data

OCTOBER 12, 2021

On 5 October 2021, the Company blazoned that it had submitted a request to the US Food and Drug Administration for Emergency Use Authorisation for AZD7442 for prophylaxis of COVID-19. Paraphernalia included 903 actors in a 11 randomisation AZD7442 to placebo. The primary analysis was grounded on 822 actors.

Trials 52

Trials Treatment Virus Disease 52

The Pharma Data

JANUARY 31, 2021

1, 2021 11:00 UTC. Our preclinical work at Gritstone developing our powerful prime-boost vaccine technology utilized simian immunodeficiency virus (SIV) derived antigens as model antigens, which are very similar to HIV-1. FOSTER CITY, Calif. & & EMERYVILLE, Calif.–( –( BUSINESS WIRE )– Gilead Sciences, Inc.

Vaccine 52

Vaccine Science Clinical Trials Licensing 52

The Pharma Data

MARCH 22, 2021

Basel, 23 March 2021 – Roche (SIX: RO, ROG; OTCQX: RHHBY) today confirmed positive topline results from the largest trial to date assessing a COVID-19 treatment in infected non-hospitalised patients (n=4,567; REGN-COV 2067). .” As soon as the novel SARS-CoV-2 virus was sequenced in early 2020, we got to work.

Clinical Trials 52

Clinical Trials Virus Trials FDA 52

The Pharma Data

MARCH 25, 2022

Discovered by Vanderbilt University Medical Center and licensed to AstraZeneca in June 2020, the human monoclonal antibodies bind to distinct sites on the SARS-CoV-2 spike protein(10) and were optimised by AstraZeneca with half-life extension and reduction of Fc effector function. 2-4 Evusheld was generally well-tolerated in the trial.(2-4).

Vaccine 52

Vaccine Virus Immune Response Trials 52

The Pharma Data

DECEMBER 30, 2020

31, 2020 /PRNewswire/ — ImmVira Group Company (“the Company”), a biotechnology platform dedicated to the development of oncolytic virus(“OV”) and vector type approaches to create more effective and safer therapies against cancer, announced today the signing of Series C financing.

Virus 40

Virus International Trials Clinical Trials 40

The Pharma Data

JANUARY 13, 2021

GMP Production of TNX-1500 is Expected to be Available in the Third Quarter of 2021. 14, 2021 (GLOBE NEWSWIRE) — Tonix Pharmaceuticals, Inc. WO 2021/001458 A1. We are developing the manufacturing processes for TNX-1500 and expect Good Manufacturing Practice (GMP) TNX-1500 to be available in the third quarter of 2021.

Pharmaceuticals 52

Pharmaceuticals Small Molecule Vaccine Protein Expression 52

The Pharma Data

JANUARY 5, 2021

5, 2021 — In late December, Dr. Ada Stewart asked her staff to check on a patient who had missed an appointment. Besides giving telemedicine a boost, the pandemic has also fostered the rise of innovative medical services, everything from getting prescriptions by mail to drive-through virus testing and pharmacy-based vaccinations.

Doctors 52

Doctors Pharmacy Vaccine Licensing 52

The Pharma Data

SEPTEMBER 7, 2021

Bristol Myers Squibb has a global exclusive license to develop, manufacture and commercialize the Rockefeller University’s novel monoclonal antibody (“mAb”) duo treatment that neutralizes the SARS-CoV-2 virus for therapy or prevention of COVID-19. We are encouraged that more than 85% of our employees in the U.S.

Clinical Trials 52

Clinical Trials Vaccine Virus Trials 52

The Pharma Data

NOVEMBER 20, 2020

In the first quarter of 2021, we expect to increase available global supply as we continue our collaboration with Roche.”. The casirivimab and imdevimab antibody cocktail is designed to mimic what a well-functioning immune system does by using very potent antibodies to neutralize the virus,” said George D. Yancopoulos, M.D.,

Therapies 52

Therapies FDA Clinical Trials Hospitals 52

The Pharma Data

JANUARY 27, 2021

– Second Product Candidate Expected to Enter Clinic in First Half of 2021. 28, 2021 (GLOBE NEWSWIRE) — Passage Bio , Inc. Passage Bio expects to initiate a Phase1/2 clinical trial for PBFT02 in the first half of 2021. PHILADELPHIA, Jan. The FDA has granted an Orphan Drug designation for PBFT02 for the treatment of FTD-GRN.

Therapies 52

Therapies Treatment Clinical Trials FDA 52

The Pharma Data

JANUARY 22, 2021

iosBio , a UK-based biotechnology company, has announced an exclusive worldwide licensing agreement with ImmunityBio , a clinical-stage immunotherapy company, for rights to use iosBio’s OraPro vaccine platform technology to test the oral administration of ImmunityBio’s vaccine candidate.

Vaccine 52

Vaccine Immune Response Government RNA 52

The Pharma Data

APRIL 6, 2021

The Prescription Drug User Fee Act (PDUFA) action date has been extended three months to early Q3 2021. ” This extension does not affect Lilly’s previously-issued financial guidance for 2021. . ” This extension does not affect Lilly’s previously-issued financial guidance for 2021.

Treatment 52

Treatment Clinical Trials Therapies Drugs 52

The Pharma Data

MARCH 2, 2021

It is licensed for commercial use by Ecología y Protección Agricola (EPA) in Valencia and provides 400 days of pest control. The launch of Vynyty Citrus ® at this year’s SHE2021 event coincides with 2021 being designated as the International Year of Fruits and Vegetables by the United Nations.

Production 52

Production International Science Licensing 52

The Pharma Data

DECEMBER 19, 2020

Healthcare workers have been on the front lines of the fight against the virus and are an inspiration to us all. Moderna will continue to gather additional data and plans to file a Biologics License Application (BLA) with the FDA requesting full licensure in 2021. Under Operation Warp Speed, the U.S. W911QY-20-C-0100.

Vaccine 52

Vaccine Long-Term Care Facilities FDA Licensing 52

The Pharma Data

OCTOBER 30, 2020

About REGN-COV2 REGN-COV2 is a combination of two monoclonal antibodies (REGN10933 and REGN10987) and was designed specifically to block infectivity of SARS-CoV-2, the virus that causes COVID-19. Regeneron has partnered with Roche to increase the global supply of REGN-COV2 beginning in 2021.

Hospitals 52

Hospitals Virus Production Clinical Trials 52

The Pharma Data

OCTOBER 14, 2020

Results from the PRECISION Study Expected in First Half of 2021. The research is part of an ongoing collaboration between Columbia University and Tonix that focuses on T cell and antibody responses to SARS-CoV-2 (CoV-2), the virus that causes COVID-19. CHATHAM, N.J., The research encompasses two projects.

Vaccine 40

Vaccine Pharmaceuticals Small Molecule Virus 40

The Pharma Data

MARCH 11, 2021

Bayer is also displaying its sense of responsibility during the COVID-19 crisis, applying its knowledge and resources to help in tackling the virus – in line with the company’s vision “Health for all, Hunger for none.” Sales growth at Bayer is planned to regain momentum in 2021 and further accelerate in the years thereafter.

Science 52

Science Pharmaceuticals Licensing Licensing 52

Codon

APRIL 2, 2023

Therapeutic neutralizing monoclonal antibody administration protects against lethal yellow fever virus infection. Read A really simple way to isolate AAVs, which are a type of virus often used to deliver gene therapies into cells. from 2021 to 2022, up to $625 million. Ricciardi M.J. Science Translational Medicine. Gene Therapy.

DNA 52

DNA RNA Engineering Licensing 52

The Pharma Data

JANUARY 12, 2021

12, 2021 /PRNewswire/ — . Under the new agreement, the government will purchase all finished doses of the casirivimab and imdevimab antibody cocktail delivered by June 30, 2021 , up to 1.25 “Additionally, as expected, the virus continues to mutate, with the possibility of developing resistance to any one antibody. .

Government 52

Government Hospitals Virus Clinical Trials 52